跳至主要内容
临床试验/NCT05496530
NCT05496530Unknown不适用

One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases

Benha University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年7月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
Visual acuity

研究概览

简要总结

Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.

详细描述

In this study, we aim to analyze the long term results of suprachoroidal injection in treating various retinal diseases to focus on its efficacy, safety and long term ocular effects as ocular hypertension, cataract progression and macular edema resolution.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • cases with central macular thickness more than 250 microns measured by optical coherence tomography due to one of the following conditions:
  • Diabetic macular edema
  • Vogt-koyanagi Harada disease
  • Retinal vein occlusion.

排除标准

  • other causes of increased macular thickness as age related macular degeneration and myopic choroidal new vascularization.
  • Cases with confirmed diagnosis of glaucoma.

研究组 & 干预措施

Diabetic macular edema

Active Comparator

Cases with diabetic macular edema with central macular thickness more than 300 microns measured by optical coherence tomography.

干预措施: Suprachoroidal triamcinolone acetonide injection (Drug)

Vogt-koyanagi harada

Active Comparator

Cases with vogt-koyanagi harada and complicated with exudative retinal detachment confirmed by optical coherence tomography.

干预措施: Suprachoroidal triamcinolone acetonide injection (Drug)

Retinal vein occlusion

Active Comparator

Cases with retinal vein occlusion and complicated with macular edema confirmed by optical coherence tomography.

干预措施: Suprachoroidal triamcinolone acetonide injection (Drug)

结局指标

主要结局

Visual acuity

时间窗: Baseline and up to one year after injection.

Changes noted in vision after injection measured 8n logMar units by snellen chart.

次要结局

  • Central macular thickness(Baseline and up to one year after injection.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Abdelshafy

Lecturer of Ophthalmology

Benha University

研究点 (1)

Loading locations...

相似试验